Mengis Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Mengis Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,916	Closed	-$326K	–	170
2023 Q2	$326K	Sell	3,916 -200	-5%	-$16.7K	0.07%	140
2023 Q1	$314K	Sell	4,116 -325	-7%	-$27K	0.07%	138
2022 Q4	$368K	Sell	4,441 -550	-11%	-$44.5K	0.08%	126
2022 Q3	$395K	Sell	4,991 -2,730	-35%	-$230K	0.09%	125
2022 Q2	$573K	Sell	7,721 -130	-2%	-$9.76K	0.13%	112
2022 Q1	$705K	Buy	7,851 +2,180	+38%	+$201K	0.14%	111
2021 Q4	$634K	Buy	5,671 +3,801	+203%	+$458K	0.12%	120
2021 Q3	$235K	Buy	1,870 +50	+3%	+$6.44K	0.05%	165
2021 Q2	$246K	Hold	1,820	–	–	0.05%	162
2021 Q1	$246K	Hold	1,820	–	–	0.05%	160
2020 Q4	$256K	Hold	1,820	–	–	0.06%	151
2020 Q3	$202K	Buy	+1,820	New	+$204K	0.06%	152

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Mengis Capital Management's XBI Position: Q3 2023 in Review

Mengis Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2023, closing a stake of 3,916 shares — an estimated $326K sold.

Mengis Capital Management first reported a position in XBI in Q3 2020 and held it in 12 quarters. The position peaked at $705K in Q1 2022. 679 funds tracked by Wall St. Rank hold XBI as of Q3 2023.

Mengis Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2023 after selling out during the quarter.
Mengis Capital Management sold 3,916 State Street SPDR S&P Biotech ETF shares in Q3 2023, an estimated $326K.
Mengis Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2020 and held it in 12 quarters.
Mengis Capital Management's State Street SPDR S&P Biotech ETF position peaked at $705K in Q1 2022.
679 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2023.

Based on Mengis Capital Management's 13F filing for Q3 2023, filed 9 Nov 2023.